Cardiac surveillance for anti-HER2 chemotherapy.

Patrick Collier, Muzna Hussain, Zoran B Popovic, Brian P Griffin

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)

Abstract

Surveillance of left ventricular function, part of current US Food and Drug Administration recommendations for anti-human epidermal growth factor receptor 2 (anti-HER2) chemotherapy, is based on historical data involving patients who received concomitant anthracycline therapy, a key enhancer of cardiac risk. More recent anti-HER2 treatment data suggest that cardiotoxicity detected by screening is rare and usually benign for patients who do not have cardiovascular risk factors and are not taking an anthracycline. Because of the burden of repetitive echocardiography required for surveillance and the risk of false-positive results, potentially leading to discontinuing lifesaving treatment, we advocate for a more focused cardiac surveillance strategy.

Original languageEnglish
Pages (from-to)110-116
Number of pages7
JournalCleveland Clinic journal of medicine
Volume88
Issue number2
DOIs
Publication statusPublished - 01 Feb 2021
Externally publishedYes

Bibliographical note

Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.

Keywords

  • Anthracyclines
  • Breast Neoplasms
  • Cardiotoxicity/etiology
  • Echocardiography
  • Female
  • Heart
  • Heart Diseases
  • Humans

Fingerprint

Dive into the research topics of 'Cardiac surveillance for anti-HER2 chemotherapy.'. Together they form a unique fingerprint.

Cite this